- Home
- DBVT vs MAX Comparison
DBVT vs MAX Comparison
Compare DBVT & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- MAX
- Stock Information
- Founded
- DBVT 2002
- MAX 2014
- Country
- DBVT France
- MAX United States
- Employees
- DBVT N/A
- MAX N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- MAX Industrial Machinery/Components
- Sector
- DBVT Health Care
- MAX Industrials
- Exchange
- DBVT Nasdaq
- MAX Nasdaq
- Market Cap
- DBVT 464.0M
- MAX 551.1M
- IPO Year
- DBVT N/A
- MAX 2020
- Fundamental
- Price
- DBVT $15.55
- MAX $11.28
- Analyst Decision
- DBVT Buy
- MAX Buy
- Analyst Count
- DBVT 4
- MAX 6
- Target Price
- DBVT $14.81
- MAX $18.17
- AVG Volume (30 Days)
- DBVT 203.8K
- MAX 413.6K
- Earning Date
- DBVT 10-28-2025
- MAX 10-29-2025
- Dividend Yield
- DBVT N/A
- MAX N/A
- EPS Growth
- DBVT N/A
- MAX N/A
- EPS
- DBVT N/A
- MAX N/A
- Revenue
- DBVT $3,800,000.00
- MAX $1,075,712,000.00
- Revenue This Year
- DBVT $1,743.46
- MAX $27.56
- Revenue Next Year
- DBVT $1,044.34
- MAX $10.79
- P/E Ratio
- DBVT N/A
- MAX N/A
- Revenue Growth
- DBVT N/A
- MAX 116.58
- 52 Week Low
- DBVT $2.21
- MAX $7.33
- 52 Week High
- DBVT $18.00
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- DBVT 60.41
- MAX 51.31
- Support Level
- DBVT $14.85
- MAX $10.49
- Resistance Level
- DBVT $16.95
- MAX $11.68
- Average True Range (ATR)
- DBVT 1.14
- MAX 0.39
- MACD
- DBVT -0.18
- MAX 0.06
- Stochastic Oscillator
- DBVT 28.24
- MAX 69.81
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.